Evinova and Bristol Myers Squibb announced a strategic partnership for the advancement of clinical trial optimization using artificial intelligence technology. The agreement utilizes Evinova’s AI technology to enhance trial designs and decision-making processes for Bristol-Myers Squibb. Bristol Myers Squibb will be able to improve productivity and hasten clinical development thanks to Evinova’s state-of-the-art technology in AI. The tools include a cost optimizer that assists with proper planning. The platform provides digital-driven insights for trial efficiency and the patient experience. Such a collaboration has the objective of reducing costs while enhancing the quality of data globally. This initiative meets the increased clinical development needs in the life sciences industry globally. Artificial Intelligence Clinical Trial Optimization leads to faster breakthroughs for innovative therapies.
Executives Highlight Urgency and Impact
Cristina Duran, President of Evinova, highlighted the importance of the need for innovation in clinical development.
“Drug development is changing rapidly, and companies need partners with AI leadership and clinical expertise,” she said. Cristian Massacesi, MD, EVP and Chief Medical Officer at Bristol Myers Squibb, stressed the urgency of transformation. “Transforming clinical development is an urgent necessity for the industry,” Cristian Massacesi said. “For years, developing medicines has taken too long, cost too much money, and mostly failed.” “Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come.” “The decisions we make now will shape the future of medicine, accelerate progress, and ensure that the benefits of scientific advancement reach those who need them most.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
